Noxopharm (ASX: NXO) is an Australian-based, clinical stage drug development company which focuses on two areas of drug technology. The first is the potential benefit to cancer patients in being able to increase their responsiveness to standard of care chemotherapies and radiotherapies. Veyonda is the first pipeline drug candidate, with later generation drug candidates under investigation in an R&D program. The second area relates to the technology behind Veyonda and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.

AppsVillage (ASX: APV) provides an easy and inexpensive SAAS solution that allows small-to-medium businesses to create and manage their own mobile application as a means of connecting with their customers and growing their business. AppsVillage’s technology has automated the design, development, maintenance and marketing of mobile apps, allowing any business to build, preview and launch their own application without having any writing or digital marketing knowledge.